Related Experiment Videos
Glutamate modulators as novel interventions for mood disorders.
Sanjay J Mathew1, Kathryn Keegan, Lisa Smith
1Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA. sanjay.mathew@mssm.edu
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)
|October 15, 2005
Summary
Novel antidepressant strategies targeting the glutamate system show promise for severe mood disorders. Compounds like ketamine and riluzole may improve neuronal resilience and offer neuroprotection.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Mood disorders involve impaired neuronal resilience.
- Monoaminergic antidepressants target neurotrophic signaling.
- Glutamate system modulation is a promising therapeutic avenue.
Purpose of the Study:
- To review pharmacological strategies targeting the glutamate system for mood disorders.
- To discuss ketamine, riluzole, and AMPA receptor potentiators.
- To explore their potential in altering disorder pathophysiology.
Main Methods:
- Focused review of scientific literature.
- Discussion of clinical investigations of specific compounds.
- Analysis of their effects on neurotrophic factors and cognition.
Main Results:
- Ketamine (NMDA receptor antagonist) shows rapid antidepressant potential.
- Riluzole reverses glutamate impairments, stimulates brain-derived neurotrophic factor.
- AMPA receptor potentiators enhance neurotrophic factors and cognition.
Conclusions:
- Glutamate system modulation offers novel therapeutic targets for severe mood disorders.
- Compounds like ketamine and riluzole show promise.
- Further controlled studies are essential.